
Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …

Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could …

Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and …

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …

Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …

The Ebola outbreak in the Democratic Republic of Congo is becoming increasingly serious, after it was confirmed that there was …

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …

A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure …

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …

Researchers from Imperial College London have discovered how to interfere with one of the building blocks that allows the common …

The FDA has noted a number of failings at a plant in Gujarat, India, but mostly significantly was the finding …

Asymptomatic carriers of malaria may be responsible for the onwards transmission of up to 90% of cases, highlighting the importance …

UK-based biotech, Emergex Vaccines, has received £1 million to push its universal flu vaccine through preclinical tests, in the hope …